AstraZeneca said its Evusheld treatment retains neutralising activity against the 'emerging and highly transmissible' Omicron BA.2 sub-variant. AP
AstraZeneca said its Evusheld treatment retains neutralising activity against the 'emerging and highly transmissible' Omicron BA.2 sub-variant. AP

AstraZeneca coronavirus drug offers protection against Omicron sub-variants in study